Patent Baristas

Ranbaxy and Teva won a victory in the U.S. Court of Appeals for the D.C. Circuit that preserved their 180-day exclusivity when patents are delisted from the FDA Orange Book. Ranbaxy et al. v. Michael O. Leavitt, Secretary of Health and Human Services et al. (06-5154). Ranbaxy and Teva had challenged the decision on the […]

A jury rejected the claims of Kourosh Dastgheib, an ophthalmologist who accused Genentech of reneging on a promise to pay him royalties from the drug in exchange for his research slides of human eye specimens. Dastgheib v. Genentech Inc., U.S. District Court, Eastern District of Pennsylvania (04CV01283). While Dastgheib’s lawyers said he was entitled to […]

If you think things are getting more expensive, it may not be your imagination. The Tufts Center for the Study of Drug Development has announced that the average cost of developing a new biotechnology product is $1.2 billion (yes, that’s with a “B”). Tufts study said the $1.2 billion estimate reflects the costs of drugs […]

I will be attending the American Conference Institute’s 7th Advanced Forum on Biotech Patents: Analysis, Insights and Strategies for New Challenges in Biotech Patent Practices in Boston, MA on November 29 and 30. I will be on a panel discussion moderated by Dennis Crouch, entitled “Roundtable Wrap Up – Reviewing the Year in Patents with […]

A new blog I came across recently is the Daily Dose of IP, a blog by Mark Reichel that is a source of daily tidbits on IP law. Daily Dose of IP (or DDIP for short), focuses on a variety of issues including patents, trademarks, copyrights and trade secrets and provides information on IP issues […]

The U.S. Court of Appeals for the Federal Circuit again hammers home the message that you can’t make a silk purse from a sow’s ear – or, at the very least, you can’t turn a known compound into an unknown (novel and, therefore, patentable) compound. In Abbott Laboratories v. Baxter Pharmaceutical Products (Fed. Cir. 06-1021, […]

Robert Ambrogi’s LawSites is running a LawSites Poll: Your Top Legal Blog. Deemed “an experiment”, Robert hopes to use the poll to deal with the flood of law blogs. Robert wants to know: What is the one law-related blog you feel you must read as regularly as possible? No fair naming your own. From your […]

Many are asking what will happen if Democrats take control of the House and Senate. While I’m not interested in taking sides, I think that the issue is certainly on everyone’s mind at the moment since it could effect how business is done after the elections. In the end, I think that the issues will […]